Leerink reiterates Eli Lilly stock rating on gene therapy progress

Leerink reiterated an Outperform rating and $1,119 price target on Eli Lilly after VERVE-102 Phase 1b data showed up to 88% PCSK9 reduction and up to 62% LDL-C lowering from a single dose. Lilly plans to start Phase 2 enrollment by year-end, while its VERVE-201 program remains ongoing and the Verve acquisition completed for $1 billion upfront in July 2025. The article also notes positive retatrutide obesity data and ongoing legal overhangs, making the overall read constructive but mixed.

Analysis

LLY’s real edge here is not the headline efficacy; it’s the option value of owning a platform that could compress lifetime treatment duration across multiple cardiovascular indications. If even one of these gene-editing programs proves durable in broader, higher-risk populations, the market will start capitalizing a much larger share of future cardiometabolic revenue today, which supports multiple expansion rather than just earnings growth. That also makes the stock increasingly less about near-term obesity momentum and more about whether Lilly can convert scientific optionality into a recurring pipeline premium.

The second-order winner is the entire cardiometabolic ecosystem, but especially device/lipid-testing and specialty infusion channels that benefit from more intensive risk stratification and patient identification. The likely loser is chronic injectable lipid therapy over the long run: not immediately in revenue, but in bargaining power, as payers will use a potentially one-and-done paradigm to pressure pricing on PCSK9s and future combination regimens. If gene editing proves even moderately scalable, the commercial disruption lands first in the highest-adherence, highest-risk cohorts, where payers are most motivated to pay upfront to avoid downstream events.

The key risk is timing: this is still a multi-year de-risking story, and the market tends to over-earn victory on Phase 1 durability. Any safety signal, redosing limitation, or narrower-than-expected genotype eligibility would quickly compress the platform multiple, especially because expectations have already been lifted by obesity franchise enthusiasm. On the other hand, a clean Phase 2 start over the next 6-12 months can keep the stock in a positive revision cycle even if monetization is years away.

Consensus is probably underpricing the strategic value of Lilly bundling obesity, cardiometabolic, and gene-editing assets into one franchise architecture. The better framing is that LLY is becoming a capital-light platform for chronic disease duration reduction; that narrative can support premium valuation through 2026 even if the gene therapy program never becomes a huge standalone profit pool. The overhang is that the market may be too willing to extrapolate platform success from a single biologic class into a broad moat, which leaves room for volatility on any incremental clinical readout.

Key Decisions for Investors

• Stay long LLY on a 6-12 month horizon; use pullbacks to add rather than chase, with the view that pipeline optionality can keep the multiple premium intact even before monetization
• Pair trade: long LLY / short a basket of chronic lipid-therapy exposure (e.g., regional PCSK9-sensitive names or broader pharma indices with limited gene-editing exposure) to express the risk of long-duration displacement over 12-24 months
• Buy LLY downside protection into the next clinical update window: 3-6 month puts or put spreads, since the stock is now more sensitive to any safety or durability miss than to upside efficacy beats
• If you want cleaner event exposure, consider a small tactical long into Phase 2 enrollment milestones, then trim into strength; the risk/reward is better on de-risking headlines than on post-announcement complacency
• Monitor payer and guideline commentary over the next 12-18 months; if reimbursement language starts assuming upfront gene-editing economics, that is the signal to increase exposure to the broader cardiometabolic platform theme